Form 4: Fate Therapeutics Insider Sells Shares for Tax Withholding
Statement of Changes in Beneficial Ownership
Fate Therapeutics reports an insider, Bahram Valamehr, sold 28,946 shares of common stock to cover tax withholding obligations related to RSU vesting.
Summary
- Bahram Valamehr, President and CEO and Director of Fate Therapeutics, sold 28,946 shares of common stock on May 20, 2026.
- The sale was executed to cover tax withholding obligations associated with the vesting of 50,000 performance-based RSUs granted on July 29, 2024.
- These sales were part of an automatic 'sell-to-cover' transaction and were not discretionary.
- The weighted average sale price for these shares ranged from $1.825 to $1.935 per share.
- Following the transaction, Valamehr beneficially owns 635,762 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the insider transaction is a standard procedure for covering tax obligations upon RSU vesting and not a discretionary sale.
Negatives
- Insider selling can sometimes be perceived negatively by the market, although this sale was for tax withholding purposes and not discretionary.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a past transaction.
Management Comments
- The sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through 'sell-to-cover' transactions and were not made at the discretion of the Reporting Person.
Industry Context
StockSavvy.ai notes that insider sales for tax withholding are common events, particularly following RSU vesting, and are generally not indicative of a negative view on the company's future prospects.
Stakeholder Impact
- Shareholders: The sale is for tax withholding and not discretionary, so it is unlikely to have a significant negative impact on share price. The market may interpret it as routine.
- Employees: This transaction is specific to the reporting person's compensation and RSU vesting.
Key Dates
| Date | Description |
|---|---|
| 07/29/2024 | Date performance-based RSUs were granted. |
| 05/20/2026 | Date of the reported stock sale transaction. |
| 05/21/2026 | Date of signature for the filing. |
Keywords
Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Fate Therapeutics, FATE, Bahram Valamehr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.